Asa Radix, M.D., M.P.H., discusses providing quality care to transgender people. It can be done.
Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa
ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
A new CDC study suggests that many urgent care centers in the U.S. still need to be made aware of pre-exposure prophylaxis and how to provide it.
However, a number of leading clinicians argue that the results should not deter care providers from prescribing PrEP for patients who are most at risk for HIV.
Some have expressed concern that, as PrEP use increases in the U.S., so will the transmission of other STIs. A new study pushes back against that worry.
In an era of HIV biomedical prevention and undetectable equals untransmittable (U=U), the primacy of condom use has changed, but the need to consider approaches to decrease STIs has not.
A substudy of the high-profile French PrEP study IPERGAY has reported alarmingly high rates of human papillomavirus (HPV) infection in HIV-negative gay men.
To gain a better understanding of the long-term effects of STI risk among PrEP users, researchers have developed a sophisticated computer simulation that can model changes in sexual behavior, PrEP adherence, STI screening and treatment and the impact...
Critics have been warning since the concept of oral PrEP was in its infancy that it would lead to major increases in condomless sex among users and a corresponding dramatic spike in STIs. So far, the data has been inconclusive.